



This summer, the Division of Pharmacoepidemiology and Clinical Pharmacology at Utrecht University, the Netherlands, offers you three challenging international summer courses. All courses will cover the key issues in each field and focus on the most important research methods used. All course teachers have extensive expertise in their field. Supplementary, there is a cultural and social programme arranged for you to make sure that you experience the best of Utrecht. We look forward to welcoming you in Utrecht!

M7 Pharmaceutical Policy Analysis (9-13 July 2018)

Medicines are among the most regulated products in society. From the earliest pre-clinical stages onward, policy makers want to foster the development of safe, effective and affordable medicines for patients in need of pharmacotherapy. When a drug reaches the market, it is the beginning of a process of complex interactions between patients, prescribers, insurers, pharmaceutical companies and governments. Furthermore, the inequity in access to medicines is still a defining characteristic of the global pharmaceutical market place.

The aim of the course is to give students insight into current developments in pharmaceutical policy making as well to give a better understanding of the methods available for analysing the effects of policy interventions. As a collaborator on this course, the World Health Organization will provide faculty for several of the sessions.

You will experience an intensive programme covering the following topics: Pharmaceutical Policy Analysis issues and methods; current challenges in drug innovation; universal health coverage; regulatory issues and challenges; country profiles; policy and politics; synthesis, case studies & public health.

Course directors

Prof. Dr. Bert Leufkens, Prof. Dr. Aukje Mantel, Dr. Rianne van den Ham and Dr. Gilles Forte (WHO)



WHO Collaborating Centre for
Pharmaceutical Policy and Regulation

M8 Pharmacoepidemiology & Drug Safety (2-6 July 2018)

With the prospect that innovative drug therapies will be introduced in the coming years, society demands new approaches and concepts for comparative risk/benefit evaluation. Assessment of safety and risk management of different drug therapies is done in the framework of observational epidemiological studies (proof of 'safety', proof of 'effectiveness'). This is the logical next step after randomized clinical trials, which are designed to provide evidence of a drugs 'efficacy'.

The course will cover key issues in pharmacoepidemiologic and drug safety research. Special topics include databases and molecular pharmacoepidemiology. Students will learn about the typical problems (e.g. confounding by indication, rare side effects) and approaches to deal with these problems in the practice of pharmacoepidemiology.

You will experience an intensive programme covering the following topics: Study Design and Methods; Confounding and other biases; Methods in drug safety research; drug safety and risk management; overview of pharmacoepidemiological databases; molecular pharmacoepidemiology; drug utilization research; synthesis, case studies & public health.

Course director

Prof. O.H. Klungel

Lecturers

Prof. S. Suissa, Prof. H.G.M. Leufkens, Prof. A. de Boer, Prof. A.C.G. Egberts, Prof. T.P. van Staa, Dr. F. de Vries





M14 Pharmacoeconomics (16-20 July 2018)

Today's society is confronted with ever increasing health care costs. One of the factors is the cost of drug innovations. Diseases waiting for therapeutic solutions are complicated and multifactorial in nature. As a result, drug innovation has become even more complex leading to high tech and therefore high cost solutions. The question arises, what is the added value of such high cost innovations and how can it be determined when both benefit and harm are considered. Health economics, and more specific pharmacoeconomics, aims to provide a neutral scientific approach to this challenge.

This course aims to provide a broad perspective of the field, including a variety of subjects from views of the different stakeholders to more in depth methodological approaches, illustrated with examples and exercises.

You will experience an intensive programme covering the following topics: pharmacoeconomic techniques; study designs and methods; critical appraisal of pharmacoeconomic studies; the (im)possibilities of the use of HTA and pharmacoeconomics in regulatory decisions; the economics of personalized medicine; pharmacoeconomics of orphan drugs.

Course director

Dr. Anke Hövels

Lecturers

Prof. Dr. Bert Leufkens, Dr. Geert Frederix, Dr. Saskia Knies, Dr. Wim Goettsch among others

General information for all courses

Target groups

(Post)graduates and professionals within governments, NGOs, industry, universities with a basic knowledge public health/medicine who have an interest in the policy aspects of pharmaceuticals, pharmacoepidemiology and/or pharmacoeconomics.

Fee and combinations

€975,- per course (including course materials + lunches + course dinner, excluding housing). Combination fee for two courses is €1550,- (excluding housing), combination fee for all three courses combined is €2025,- (excluding housing).

Deadline for application

17 June 2018, see www.utrechtsummerschool.nl (information summer school and course registration)

More information

Course coordinator: Nienke Op 't Hoog (pharm.summercourses@gmail.com)

